All In Biotech

Drug Trial Radar · NCT06742723

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 5,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,000

Planned (sponsor's estimate)

Start

Mar 3, 2025

Primary completion

Dec 18, 2029

Study completion Dec 18, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

Conditions

  • Chronic Kidney Disease and Hypertension

Interventions

  • Baxdrostat/dapagliflozinDrug

    baxdrostat tablet dapagliflozin tablet

  • Placebo/dapagliflozinDrug

    dapagliflozin tablet placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine whether baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of the composite endpoint of ≥ 50% sustained decline in eGFR, kidney failure, Heart Failure events(HF), or CV death.Time frame: Up to 37 months

Locations

771 sites in 42 countries. Site status is shown where the registry gives one.

  • Research Site

    Fairhope, Alabama · Recruiting

  • Research Site

    Sun City, Arizona · Recruiting

  • Research Site

    Tucson, Arizona · Recruiting

  • Research Site

    Beverly Hills, California · Recruiting

  • Research Site

    Canoga Park, California · Withdrawn

  • Research Site

    Concord, California · Recruiting

  • Research Site

    Fremont, California · Recruiting

  • Research Site

    Fullerton, California · Recruiting

  • Research Site

    Inglewood, California · Withdrawn

  • Research Site

    Los Alamitos, California · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    San Diego, California · Withdrawn

  • Research Site

    San Francisco, California · Withdrawn

  • Research Site

    Stanford, California · Recruiting

  • Research Site

    Tarzana, California · Recruiting

  • Research Site

    Arvada, Colorado · Recruiting

  • Research Site

    Denver, Colorado · Withdrawn

  • Research Site

    New Britain, Connecticut · Recruiting

  • Research Site

    Washington D.C., District of Columbia · Recruiting

  • Research Site

    Boca Raton, Florida · Recruiting

  • Research Site

    Boynton Beach, Florida · Recruiting

  • Research Site

    Edgewater, Florida · Recruiting

  • Research Site

    Fort Lauderdale, Florida · Recruiting

  • Research Site

    Hollywood, Florida · Recruiting

  • Research Site

    Jacksonville Beach, Florida · Recruiting

  • Research Site

    Lake City, Florida · Recruiting

  • Research Site

    Lakeland, Florida · Recruiting

  • Research Site

    Melbourne, Florida · Recruiting

  • Research Site

    Miami Lakes, Florida · Suspended

  • Research Site

    Ocoee, Florida · Recruiting

  • Research Site

    Port Charlotte, Florida · Recruiting

  • Research Site

    Port Charlotte, Florida · Completed

  • Research Site

    Port Orange, Florida · Recruiting

  • Research Site

    Riverview, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Recruiting

  • Research Site

    Augusta, Georgia · Withdrawn

  • Research Site

    Austell, Georgia · Recruiting

  • Research Site

    Brunswick, Georgia · Recruiting

  • Research Site

    Conyers, Georgia · Recruiting

  • Research Site

    Decatur, Georgia · Recruiting

Showing 40 of 771 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.